Meta-analysis of 24 phase 3 trials (5546 patients) in untreated advanced NSCLC with PD-L1 ≥50%: indirect comparison associated chemoimmunotherapy with longer OS than PD-(L)1 inhibitor monotherapy (network HR 0.85; median 29.2 vs 19.8 months in reconstructed data).
Meta-analysisn = 5,546
Di Federico et al. PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis